New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Zymeworks Presents Preclinical Data on TLR7 ISACs technology at the Society for Immunotherapy of Cancer (SITC) Conference
Today we presented preclinical data associated with our TLR7 ISACs technology. The poster presentation titled “Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)” shows the potential of using novel purine-based TLR7 agonists as payloads for ISACs. ISACs consist of antibodies conjugated to immune stimulants and are designed to induce antitumor immune […]
November is Stomach Cancer Awareness Month
Stomach Cancer is the fifth most common cancer worldwide, with more than 1 million new cases diagnosed globally each year. National Stomach Cancer Month runs through November, and Zymeworks is joining forces with leading stomach cancer advocacy organizations to raise awareness. Please join Zymeworks and our advocacy partners, including Debbie’s Dream Foundation, Gastric Cancer Foundation, Digestive Cancers Europe and My […]
Zymeworks Early R&D Day Highlights Progress In Development Of Novel Pipeline Assets And Applications Of Proprietary Next-Generation Technology Platforms
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Zymeworks to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) Conference
Zymeworks is pleased to announce the acceptance of an abstract for poster presentation at the Society for Immunotherapy of Cancer (SITC) Conference taking place in Boston, MA from November 8 to November 12, 2022. Presentation Details: Title: Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs) Poster Number: 1185 Date and Time: November […]
Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day
Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results
Zymeworks Announces Participation In Upcoming Investor Conferences
